Please assess the completion status of the following clinical trial:

Trial Title: Cardiometabolic Disease and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-80 years~* History of obesity and current BMI ≥ 25 kg/ m2 for study volunteers or BMI ≥ 25 kg/ m2 for those with clinically indicated CPET or known HFpEF~* History of Dyspnea (Grade 1 or more)~* Able to provide informed consent and willing to comply with study~Exclusion Criteria:~* History of diabetes mellitus~* History of primary pulmonary arterial hypertension~* History of moderate to severe COPD~* History of severe Obstructive Sleep apnea~* History of renal disease (eGFR\< 45 mL/min/1.732)~* History of severe liver disease~* History of cardiovascular disease (recent heart attack or stroke) except known HFpEF~* History of blood clot in lung~* History of Splenectomy~* History of Active Cancer~* Platelets count of \< 75,000~* International normalized ration (INR) of \> 1.5~* History of recent anemia (HB \< 9g/dL)~* Current use of Metformin~* Prior LVEF \< 50% on echocardiogram~* Indication of severe valvular disease on echo~* Pregnant or planning to become pregnant in next 4 months~* History of HIV infection

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).